Literature DB >> 31813120

The P2X7 Receptor in the Maintenance of Cancer Stem Cells, Chemoresistance and Metastasis.

Vanessa Fernandes Arnaud-Sampaio1, Izadora Lorrany Alves Rabelo1, Henning Ulrich1, Claudiana Lameu2.   

Abstract

Metastasis is the worst prognosis predictor in the clinical course of cancer development. Features of metastatic cancer cells include migratory ability, low degree of differentiation, self-renewal and proliferation potentials, as well as resistance to therapies. Metastatic cells do not present all of the necessary characteristics at once. Indeed, they have a unique phenotypic plasticity, allowing the acquisition of features that make them successful in all steps of metastasis. Cancer stem cells (CSC), the most undifferentiated cells in the tumor mass, display highest metastatic potential and resistance to radio- and chemotherapy. Growing tumors exhibit marked upregulation of P2X7 receptor expression and secrete ATP. Since the P2X7 receptor plays an important role in the maintenance of undifferentiated state of pluripotent cells, its importance on cell fate regulation in the tumor mass is suggested. Considering the extensive crosstalk between CSCs, epithelial-mesenchymal transition, drug resistance and metastasis, current knowledge implicating P2X7 receptor function in these phenomena and new avenues for therapeutic strategies to control metastasis are reviewed.

Entities:  

Keywords:  Cancer stem cells; Drug resistance; Epithelial-mesenchymal transition; Metastasis; P2X7 receptor; Purinergic signaling

Mesh:

Substances:

Year:  2020        PMID: 31813120     DOI: 10.1007/s12015-019-09936-w

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  158 in total

1.  Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes.

Authors:  Shigeomi Shimizu; Toku Kanaseki; Noboru Mizushima; Takeshi Mizuta; Satoko Arakawa-Kobayashi; Craig B Thompson; Yoshihide Tsujimoto
Journal:  Nat Cell Biol       Date:  2004-11-21       Impact factor: 28.824

2.  The role of pannexin 1 hemichannels in ATP release and cell-cell communication in mouse taste buds.

Authors:  Yi-Jen Huang; Yutaka Maruyama; Gennady Dvoryanchikov; Elizabeth Pereira; Nirupa Chaudhari; Stephen D Roper
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-26       Impact factor: 11.205

3.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.

Authors:  Julie Caramel; Eftychios Papadogeorgakis; Louise Hill; Gareth J Browne; Geoffrey Richard; Anne Wierinckx; Gerald Saldanha; Joy Osborne; Peter Hutchinson; Gina Tse; Joël Lachuer; Alain Puisieux; J Howard Pringle; Stéphane Ansieau; Eugene Tulchinsky
Journal:  Cancer Cell       Date:  2013-09-26       Impact factor: 31.743

4.  VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.

Authors:  Oscar Gonzalez-Moreno; Jon Lecanda; Jeffrey E Green; Victor Segura; Raul Catena; Diego Serrano; Alfonso Calvo
Journal:  Exp Cell Res       Date:  2009-12-16       Impact factor: 3.905

5.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

6.  Accelerated tumor progression in mice lacking the ATP receptor P2X7.

Authors:  Elena Adinolfi; Marina Capece; Alessia Franceschini; Simonetta Falzoni; Anna L Giuliani; Alessandra Rotondo; Alba C Sarti; Massimo Bonora; Susanne Syberg; Domenica Corigliano; Paolo Pinton; Niklas R Jorgensen; Luigi Abelli; Laura Emionite; Lizzia Raffaghello; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2014-12-26       Impact factor: 12.701

Review 7.  Extracellular purines, purinergic receptors and tumor growth.

Authors:  F Di Virgilio; E Adinolfi
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

8.  Highly Selective Anti-Cancer Activity of Cholesterol-Interacting Agents Methyl-β-Cyclodextrin and Ostreolysin A/Pleurotolysin B Protein Complex on Urothelial Cancer Cells.

Authors:  Nataša Resnik; Urška Repnik; Mateja Erdani Kreft; Kristina Sepčić; Peter Maček; Boris Turk; Peter Veranič
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

9.  Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma.

Authors:  Anna Lisa Giuliani; Davide Colognesi; Tiziana Ricco; Carlotta Roncato; Marina Capece; Francesca Amoroso; Qi Guang Wang; Elena De Marchi; Allison Gartland; Francesco Di Virgilio; Elena Adinolfi
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

10.  P2X7 mediates ATP-driven invasiveness in prostate cancer cells.

Authors:  Ying Qiu; Wei-Hua Li; Hong-Quan Zhang; Yan Liu; Xin-Xia Tian; Wei-Gang Fang
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

View more
  11 in total

1.  Administration of P2X7 Receptor Blockers in Oncological Experimental Models.

Authors:  Elena De Marchi; Anna Pegoraro; Elena Adinolfi
Journal:  Methods Mol Biol       Date:  2022

2.  Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling.

Authors:  Davide Ferrari; Stefania Gessi; Stefania Merighi; Manuela Nigro; Alessia Travagli; Jorge S Burns
Journal:  Front Cell Dev Biol       Date:  2022-05-04

3.  A2A Receptor Contributes to Tumor Progression in P2X7 Null Mice.

Authors:  Elena De Marchi; Anna Pegoraro; Roberta Turiello; Francesco Di Virgilio; Silvana Morello; Elena Adinolfi
Journal:  Front Cell Dev Biol       Date:  2022-05-18

Review 4.  P2X7 receptor: a critical regulator and potential target for breast cancer.

Authors:  Xiaodi Zhu; Qianqian Li; Wei Song; Xiaoxiang Peng; Ronglan Zhao
Journal:  J Mol Med (Berl)       Date:  2021-01-23       Impact factor: 4.599

Review 5.  Targeting the purinergic pathway in breast cancer and its therapeutic applications.

Authors:  Julia Beatrice de Araújo; Vanessa Vitória Kerkhoff; Sarah Franco Vieira de Oliveira Maciel; Débora Tavares de Resende E Silva
Journal:  Purinergic Signal       Date:  2021-02-12       Impact factor: 3.765

6.  Expression Pattern of Purinergic Signaling Components in Colorectal Cancer Cells and Differential Cellular Outcomes Induced by Extracellular ATP and Adenosine.

Authors:  Clémentine Dillard; Chloé Borde; Ammara Mohammad; Virginie Puchois; Laurent Jourdren; Annette K Larsen; Michèle Sabbah; Vincent Maréchal; Alexandre E Escargueil; Elodie Pramil
Journal:  Int J Mol Sci       Date:  2021-10-25       Impact factor: 5.923

Review 7.  The Role of Purinergic P2X7 Receptor in Inflammation and Cancer: Novel Molecular Insights and Clinical Applications.

Authors:  John Charles Rotondo; Chiara Mazziotta; Carmen Lanzillotti; Chiara Stefani; Giada Badiale; Giulia Campione; Fernanda Martini; Mauro Tognon
Journal:  Cancers (Basel)       Date:  2022-02-22       Impact factor: 6.639

Review 8.  Targeting purine metabolism in ovarian cancer.

Authors:  Jingchun Liu; Shasha Hong; Jiang Yang; Xiaoyi Zhang; Ying Wang; Haoyu Wang; Jiaxin Peng; Li Hong
Journal:  J Ovarian Res       Date:  2022-08-13       Impact factor: 5.506

Review 9.  Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance.

Authors:  Hamid Aria; Marzieh Rezaei; Shima Nazem; Abdolreza Daraei; Ghasem Nikfar; Behnam Mansoori; Maryam Bahmanyar; Alireza Tavassoli; Mohammad Kazem Vakil; Yaser Mansoori
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

10.  Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer.

Authors:  Haiyun Zhang; Alexander Steed; Milo Co; Xiaozhuo Chen
Journal:  Cancer Drug Resist       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.